Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 375 participants.

Also called NCT04251156

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 375 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04251156
Other papers using this trial's data
  • Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial The lancet. Diabetes & endocrinology, 2024-03 DOI, PubMed 38330988

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Brazil, China, Hong Kong SAR China, South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04251156. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-08 (actual); primary completion 2022-08-23 (actual). Results posted on 2024-11-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
Acronym
STEP7
Condition
Overweight
Condition
Obesity
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo (semaglutide)
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct04251156
Content hash
f1e4868244e99dbd6dcc9319130def8935f82d1860d6b95def96e06847ebf400